Overview

Study of Oxaliplatin Plus Bevacizumab in Germ Cell Tumor Patients

Status:
Completed
Trial end date:
2014-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the effectiveness of oxaliplatin and bevacizumab in patients with refractory or relapsed germ cell tumors.
Phase:
Phase 2
Details
Lead Sponsor:
Indiana University
Collaborator:
Genentech, Inc.
Treatments:
Bevacizumab
Oxaliplatin